Literature DB >> 32344399

Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.

Ione O C Woollacott1, Jennifer M Nicholas2, Carolin Heller3, Martha S Foiani3, Katrina M Moore1, Lucy L Russell1, Ross W Paterson1, Ashvini Keshavan1, Jonathan M Schott1, Jason D Warren1, Amanda Heslegrave3, Henrik Zetterberg3,4,5, Jonathan D Rohrer6.   

Abstract

BACKGROUND: Chronic glial dysfunction may contribute to the pathogenesis of frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) levels of glia-derived proteins YKL-40 and chitotriosidase are increased in Alzheimer's disease (AD) but have not been explored in detail across the spectrum of FTD.
METHODS: We investigated whether CSF YKL-40 and chitotriosidase levels differed between FTD patients and controls, across different clinical and genetic subtypes of FTD, and between individuals with a clinical FTD syndrome due to AD versus non-AD (frontotemporal lobar degeneration, FTLD) pathology (based on CSF neurodegenerative biomarkers). Eighteen healthy controls and 64 people with FTD (behavioural variant FTD, n = 20; primary progressive aphasia [PPA], n = 44: nfvPPA, n = 16, svPPA, n = 11, lvPPA, n = 14, PPA-NOS, n = 3) were included. 10/64 had familial FTD, with mutations in GRN(n = 3), MAPT(n = 4), or C9orf72 (n = 3). 15/64 had neurodegenerative biomarkers consistent with AD pathology. Levels were measured by immunoassay and compared using multiple linear regressions. We also examined relationships of YKL-40 and chitotriosidase with CSF total tau (T-tau), phosphorylated tau 181 (P-tau) and β-amyloid 1-42 (Aβ42), with each other, and with age and disease du-ration.
RESULTS: CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. GRN mutation carriers had higher levels of both proteins than controls and C9orf72 expansion carriers, and YKL-40 was higher in MAPT mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and Aβ42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not chitotriosidase was associated with age, but not disease duration.
CONCLUSION: CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to GRN mutations, while YKL-40 is increased in individuals with MAPT mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Astrocytes; Biomarkers; CHI3L1; Cerebrospinal fluid; Chitotriosidase; Frontotemporal dementia; Microglia; Neuroinflammation; Progranulin; YKL-40

Mesh:

Substances:

Year:  2020        PMID: 32344399      PMCID: PMC7513620          DOI: 10.1159/000506282

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  95 in total

1.  Asymmetric TDP pathology in primary progressive aphasia with right hemisphere language dominance.

Authors:  Garam Kim; Shahrooz Vahedi; Tamar Gefen; Sandra Weintraub; Eileen H Bigio; Marek-Marsel Mesulam; Changiz Geula
Journal:  Neurology       Date:  2018-01-05       Impact factor: 9.910

2.  TDP-43 frontotemporal lobar degeneration and autoimmune disease.

Authors:  Zachary A Miller; Katherine P Rankin; Neill R Graff-Radford; Leonel T Takada; Virginia E Sturm; Clare M Cleveland; Lindsey A Criswell; Philipp A Jaeger; Trisha Stan; Kristin A Heggeli; Sandy Chan Hsu; Anna Karydas; Baber K Khan; Lea T Grinberg; Maria Luisa Gorno-Tempini; Adam L Boxer; Howard J Rosen; Joel H Kramer; Giovanni Coppola; Daniel H Geschwind; Rosa Rademakers; William W Seeley; Tony Wyss-Coray; Bruce L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-30       Impact factor: 10.154

3.  Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia.

Authors:  D T Ohm; G Kim; T Gefen; A Rademaker; S Weintraub; E H Bigio; M-M Mesulam; E Rogalski; C Geula
Journal:  Neuropathol Appl Neurobiol       Date:  2018-05-17       Impact factor: 8.090

4.  Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

Authors:  E R Peskind; W S Griffin; K T Akama; M A Raskind; L J Van Eldik
Journal:  Neurochem Int       Date:  2001 Nov-Dec       Impact factor: 3.921

5.  Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.

Authors:  Hansen Lui; Jiasheng Zhang; Stefanie R Makinson; Michelle K Cahill; Kevin W Kelley; Hsin-Yi Huang; Yulei Shang; Michael C Oldham; Lauren Herl Martens; Fuying Gao; Giovanni Coppola; Steven A Sloan; Christine L Hsieh; Charles C Kim; Eileen H Bigio; Sandra Weintraub; Marek-Marsel Mesulam; Rosa Rademakers; Ian R Mackenzie; William W Seeley; Anna Karydas; Bruce L Miller; Barbara Borroni; Roberta Ghidoni; Robert V Farese; Jeanne T Paz; Ben A Barres; Eric J Huang
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

6.  Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Authors:  Daniel Alcolea; María Carmona-Iragui; Marc Suárez-Calvet; M Belén Sánchez-Saudinós; Isabel Sala; Sofía Antón-Aguirre; Rafael Blesa; Jordi Clarimón; Juan Fortea; Alberto Lleó
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Authors:  Kelsey E Melah; Sharon Yuan-Fu Lu; Siobhan M Hoscheidt; Andrew L Alexander; Nagesh Adluru; Daniel J Destiche; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Carey E Gleason; N Maritza Dowling; Lisa C Bratzke; Howard A Rowley; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

8.  Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.

Authors:  Charlotte E Teunissen; Naura Elias; Marleen J A Koel-Simmelink; Sisi Durieux-Lu; Arjan Malekzadeh; Thang V Pham; Sander R Piersma; Tommaso Beccari; Lieke H H Meeter; Elise G P Dopper; John C van Swieten; Connie R Jimenez; Yolande A L Pijnenburg
Journal:  Alzheimers Dement (Amst)       Date:  2016-01-19

9.  Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia.

Authors:  Ione O C Woollacott; Martina Bocchetta; Carole H Sudre; Basil H Ridha; Catherine Strand; Robert Courtney; Sebastien Ourselin; M Jorge Cardoso; Jason D Warren; Martin N Rossor; Tamas Revesz; Nick C Fox; Janice L Holton; Tammaryn Lashley; Jonathan D Rohrer
Journal:  Neurocase       Date:  2018-08-16       Impact factor: 0.881

10.  Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.

Authors:  Wolfgang J Streit; Heiko Braak; Qing-Shan Xue; Ingo Bechmann
Journal:  Acta Neuropathol       Date:  2009-06-10       Impact factor: 17.088

View more
  6 in total

1.  Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.

Authors:  Kevin Connolly; Mikael Lehoux; Ryan O'Rourke; Benedetta Assetta; Guzide Ayse Erdemir; Jack A Elias; Chun Geun Lee; Yu-Wen Alvin Huang
Journal:  Alzheimers Dement       Date:  2022-03-02       Impact factor: 16.655

Review 2.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

Review 3.  Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jared S Katzeff; Fiona Bright; Katherine Phan; Jillian J Kril; Lars M Ittner; Michael Kassiou; John R Hodges; Olivier Piguet; Matthew C Kiernan; Glenda M Halliday; Woojin Scott Kim
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

Review 4.  The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD.

Authors:  Pegah Masrori; Jimmy Beckers; Helena Gossye; Philip Van Damme
Journal:  Mol Neurodegener       Date:  2022-03-18       Impact factor: 14.195

5.  YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Yanaika S Hok-A-Hin; Jeroen J M Hoozemans; William T Hu; Dorine Wouters; Jennifer C Howell; Alberto Rábano; Wiesje M van der Flier; Yolande A L Pijnenburg; Charlotte E Teunissen; Marta Del Campo
Journal:  Alzheimers Res Ther       Date:  2022-07-25       Impact factor: 8.823

6.  Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.

Authors:  Emma L van der Ende; Carolin Heller; Jonathan D Rohrer; Harro Seelaar; Aitana Sogorb-Esteve; Imogen J Swift; David McFall; Georgia Peakman; Arabella Bouzigues; Jackie M Poos; Lize C Jiskoot; Jessica L Panman; Janne M Papma; Lieke H Meeter; Elise G P Dopper; Martina Bocchetta; Emily Todd; David Cash; Caroline Graff; Matthis Synofzik; Fermin Moreno; Elizabeth Finger; Raquel Sanchez-Valle; Rik Vandenberghe; Robert Laforce; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Chris Butler; Simon Ducharme; Alexander Gerhard; Adrian Danek; Johannes Levin; Yolande A L Pijnenburg; Markus Otto; Barbara Borroni; Fabrizio Tagliavini; Alexandre de Mendonça; Isabel Santana; Daniela Galimberti; Sandro Sorbi; Henrik Zetterberg; Eric Huang; John C van Swieten
Journal:  J Neuroinflammation       Date:  2022-09-05       Impact factor: 9.587

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.